Last reviewed · How we verify
Zilovertamab
Zilovertamab is a Small molecule drug developed by Oncternal Therapeutics, Inc. It is currently in discontinued development. Also known as: Cirmtuzumab, UC961.
At a glance
| Generic name | Zilovertamab |
|---|---|
| Also known as | Cirmtuzumab, UC961 |
| Sponsor | Oncternal Therapeutics, Inc |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- A Phase 1b Pilot Clinical Trial of Cirmtuzumab, an Anti-ROR1 Monoclonal Antibody, in Combination With Paclitaxel for the Treatment of Patients With Metastatic, or Locally Advanced, Unresectable Breast (Phase 1)
- A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP in Participants With DLBCL (waveLINE) (Phase 2)
- A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-004) (Phase 2)
- A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B (Phase 2)
- A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma ( (Phase 3)
- A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects With Hematological Malignancies (waveLINE-001) (Phase 1)
- Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax (Phase 2)
- A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participan (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zilovertamab CI brief — competitive landscape report
- Zilovertamab updates RSS · CI watch RSS
- Oncternal Therapeutics, Inc portfolio CI
Frequently asked questions about Zilovertamab
What is Zilovertamab?
Zilovertamab is a Small molecule drug developed by Oncternal Therapeutics, Inc.
Who makes Zilovertamab?
Zilovertamab is developed by Oncternal Therapeutics, Inc (see full Oncternal Therapeutics, Inc pipeline at /company/oncternal-therapeutics-inc).
Is Zilovertamab also known as anything else?
Zilovertamab is also known as Cirmtuzumab, UC961.
What development phase is Zilovertamab in?
Zilovertamab is in discontinued.
Related
- Manufacturer: Oncternal Therapeutics, Inc — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Cirmtuzumab, UC961
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing